Proof of Concept: Matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes

Karen Frankwich, Courtney Tibble, Moises Torres-Gonzalez, Mariah Bonner, Roy Lefkowitz, Matt Tyndall, Geert W. Schmid-Schönbein, Francisco Villarreal, Michael (Mike) Heller, Karen Herbst

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Obesity is a state of subclinical inflammation resulting in loss of function of insulin receptors and decreased insulin sensitivity. Inhibition of the inflammatory enzymes, matrix metalloproteinases (MMPs), for 6 months in rodent models restores insulin receptor function and insulin sensitivity. Methods: This 12-week double-blind, randomized, placebo (PL)-controlled proof-of-concept study was performed to determine if the MMP inhibitor (MMPI), doxycycline, decreased global markers of inflammation and enhanced muscle insulin sensitivity in obese people with type 2 diabetes (DM2). The study included non-DM2 controls (n = 15), and DM2 subjects randomized to PL (n = 13) or doxycycline 100 mg twice daily (MMPI; n = 11). All participants were evaluated on Day 1; MMPI and PL groups were also evaluated after 84 days of treatment. Results: There was a significant decrease in inflammatory markers C-reactive protein (P < 0.05) and myeloperoxidase (P = 0.01) in the MMPI but not PL group. The MMPI also significantly increased skeletal muscle activated/total insulin signaling mediators: 3'phosphoinositide kinase-1 (PDK1) (p < 0.03), protein kinase B (PKB/Akt) (p < 0.004), and glycogen synthase kinase 3ß (GSK3ß) (p < 0.03). Conclusions: This study demonstrated short term treatment of people with diabetes with an MMPI resulted in decreased inflammation and improved insulin sensitivity. Larger, longer studies are warranted to determine if doxycycline can improve glucose control in people with diabetes.

Original languageEnglish (US)
Article number9
JournalJournal of Inflammation (United Kingdom)
Volume9
Issue number1
DOIs
StatePublished - Oct 1 2012
Externally publishedYes

Fingerprint

Matrix Metalloproteinase Inhibitors
Medical problems
Type 2 Diabetes Mellitus
Muscle
Insulin Resistance
Insulin
Inflammation
Muscles
Doxycycline
Placebos
Insulin Receptor
Glycogen Synthase Kinase 3
Proto-Oncogene Proteins c-akt
1-Phosphatidylinositol 4-Kinase
Matrix Metalloproteinases
C-Reactive Protein
Peroxidase
Rodentia
Skeletal Muscle
Obesity

Keywords

  • Diabetes
  • Doxycycline
  • Insulin sensitivity
  • Matrix metalloproteinases
  • Myeloperoxidase

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology

Cite this

Proof of Concept : Matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes. / Frankwich, Karen; Tibble, Courtney; Torres-Gonzalez, Moises; Bonner, Mariah; Lefkowitz, Roy; Tyndall, Matt; Schmid-Schönbein, Geert W.; Villarreal, Francisco; Heller, Michael (Mike); Herbst, Karen.

In: Journal of Inflammation (United Kingdom), Vol. 9, No. 1, 9, 01.10.2012.

Research output: Contribution to journalArticle

Frankwich, K, Tibble, C, Torres-Gonzalez, M, Bonner, M, Lefkowitz, R, Tyndall, M, Schmid-Schönbein, GW, Villarreal, F, Heller, MM & Herbst, K 2012, 'Proof of Concept: Matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes', Journal of Inflammation (United Kingdom), vol. 9, no. 1, 9. https://doi.org/10.1186/1476-9255-9-35
Frankwich, Karen ; Tibble, Courtney ; Torres-Gonzalez, Moises ; Bonner, Mariah ; Lefkowitz, Roy ; Tyndall, Matt ; Schmid-Schönbein, Geert W. ; Villarreal, Francisco ; Heller, Michael (Mike) ; Herbst, Karen. / Proof of Concept : Matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes. In: Journal of Inflammation (United Kingdom). 2012 ; Vol. 9, No. 1.
@article{2747dde68add45ffa2971dcd0641a52b,
title = "Proof of Concept: Matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes",
abstract = "Background: Obesity is a state of subclinical inflammation resulting in loss of function of insulin receptors and decreased insulin sensitivity. Inhibition of the inflammatory enzymes, matrix metalloproteinases (MMPs), for 6 months in rodent models restores insulin receptor function and insulin sensitivity. Methods: This 12-week double-blind, randomized, placebo (PL)-controlled proof-of-concept study was performed to determine if the MMP inhibitor (MMPI), doxycycline, decreased global markers of inflammation and enhanced muscle insulin sensitivity in obese people with type 2 diabetes (DM2). The study included non-DM2 controls (n = 15), and DM2 subjects randomized to PL (n = 13) or doxycycline 100 mg twice daily (MMPI; n = 11). All participants were evaluated on Day 1; MMPI and PL groups were also evaluated after 84 days of treatment. Results: There was a significant decrease in inflammatory markers C-reactive protein (P < 0.05) and myeloperoxidase (P = 0.01) in the MMPI but not PL group. The MMPI also significantly increased skeletal muscle activated/total insulin signaling mediators: 3'phosphoinositide kinase-1 (PDK1) (p < 0.03), protein kinase B (PKB/Akt) (p < 0.004), and glycogen synthase kinase 3{\ss} (GSK3{\ss}) (p < 0.03). Conclusions: This study demonstrated short term treatment of people with diabetes with an MMPI resulted in decreased inflammation and improved insulin sensitivity. Larger, longer studies are warranted to determine if doxycycline can improve glucose control in people with diabetes.",
keywords = "Diabetes, Doxycycline, Insulin sensitivity, Matrix metalloproteinases, Myeloperoxidase",
author = "Karen Frankwich and Courtney Tibble and Moises Torres-Gonzalez and Mariah Bonner and Roy Lefkowitz and Matt Tyndall and Schmid-Sch{\"o}nbein, {Geert W.} and Francisco Villarreal and Heller, {Michael (Mike)} and Karen Herbst",
year = "2012",
month = "10",
day = "1",
doi = "10.1186/1476-9255-9-35",
language = "English (US)",
volume = "9",
journal = "Journal of inflammation",
issn = "1078-7852",
publisher = "Springer Nature",
number = "1",

}

TY - JOUR

T1 - Proof of Concept

T2 - Matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes

AU - Frankwich, Karen

AU - Tibble, Courtney

AU - Torres-Gonzalez, Moises

AU - Bonner, Mariah

AU - Lefkowitz, Roy

AU - Tyndall, Matt

AU - Schmid-Schönbein, Geert W.

AU - Villarreal, Francisco

AU - Heller, Michael (Mike)

AU - Herbst, Karen

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Background: Obesity is a state of subclinical inflammation resulting in loss of function of insulin receptors and decreased insulin sensitivity. Inhibition of the inflammatory enzymes, matrix metalloproteinases (MMPs), for 6 months in rodent models restores insulin receptor function and insulin sensitivity. Methods: This 12-week double-blind, randomized, placebo (PL)-controlled proof-of-concept study was performed to determine if the MMP inhibitor (MMPI), doxycycline, decreased global markers of inflammation and enhanced muscle insulin sensitivity in obese people with type 2 diabetes (DM2). The study included non-DM2 controls (n = 15), and DM2 subjects randomized to PL (n = 13) or doxycycline 100 mg twice daily (MMPI; n = 11). All participants were evaluated on Day 1; MMPI and PL groups were also evaluated after 84 days of treatment. Results: There was a significant decrease in inflammatory markers C-reactive protein (P < 0.05) and myeloperoxidase (P = 0.01) in the MMPI but not PL group. The MMPI also significantly increased skeletal muscle activated/total insulin signaling mediators: 3'phosphoinositide kinase-1 (PDK1) (p < 0.03), protein kinase B (PKB/Akt) (p < 0.004), and glycogen synthase kinase 3ß (GSK3ß) (p < 0.03). Conclusions: This study demonstrated short term treatment of people with diabetes with an MMPI resulted in decreased inflammation and improved insulin sensitivity. Larger, longer studies are warranted to determine if doxycycline can improve glucose control in people with diabetes.

AB - Background: Obesity is a state of subclinical inflammation resulting in loss of function of insulin receptors and decreased insulin sensitivity. Inhibition of the inflammatory enzymes, matrix metalloproteinases (MMPs), for 6 months in rodent models restores insulin receptor function and insulin sensitivity. Methods: This 12-week double-blind, randomized, placebo (PL)-controlled proof-of-concept study was performed to determine if the MMP inhibitor (MMPI), doxycycline, decreased global markers of inflammation and enhanced muscle insulin sensitivity in obese people with type 2 diabetes (DM2). The study included non-DM2 controls (n = 15), and DM2 subjects randomized to PL (n = 13) or doxycycline 100 mg twice daily (MMPI; n = 11). All participants were evaluated on Day 1; MMPI and PL groups were also evaluated after 84 days of treatment. Results: There was a significant decrease in inflammatory markers C-reactive protein (P < 0.05) and myeloperoxidase (P = 0.01) in the MMPI but not PL group. The MMPI also significantly increased skeletal muscle activated/total insulin signaling mediators: 3'phosphoinositide kinase-1 (PDK1) (p < 0.03), protein kinase B (PKB/Akt) (p < 0.004), and glycogen synthase kinase 3ß (GSK3ß) (p < 0.03). Conclusions: This study demonstrated short term treatment of people with diabetes with an MMPI resulted in decreased inflammation and improved insulin sensitivity. Larger, longer studies are warranted to determine if doxycycline can improve glucose control in people with diabetes.

KW - Diabetes

KW - Doxycycline

KW - Insulin sensitivity

KW - Matrix metalloproteinases

KW - Myeloperoxidase

UR - http://www.scopus.com/inward/record.url?scp=84866789438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866789438&partnerID=8YFLogxK

U2 - 10.1186/1476-9255-9-35

DO - 10.1186/1476-9255-9-35

M3 - Article

C2 - 23025537

AN - SCOPUS:84866789438

VL - 9

JO - Journal of inflammation

JF - Journal of inflammation

SN - 1078-7852

IS - 1

M1 - 9

ER -